[1] |
Roger VT . Heart disease and stroke statistics-2011 update:a report from the American Heart Association[J]. Circulation, 2011,123(4):18-209.
|
[2] |
Hacke W, Kaste M, Bluhmki E , et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J]. J Vascular Surgery, 2008,48(6):1634-1635.
|
[3] |
Emberson J, Lees KR, Lyden P , et al. Effect of treatment delay,age,and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke:a meta-analysis of individual patient data from randomised trials[J]. Lancet, 2014,384(9958):1929-1935
|
[4] |
Strbian D, Sairanen T, Meretoja A , et al. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis[J]. Neurology, 2011,77(4):341-348.
|
[5] |
Whiteley WN, Emberson J, Lees KR , et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke:a secondary analysis of an individual patient data meta-analysis[J]. Lancet Neurology, 2016,15(9):925-933.
|
[6] |
常红, 王晓娟 . 阿替普酶静脉溶栓治疗急性缺血性脑卒中溶栓后出血发生时间的观察[J]. 中华护理杂志, 2014,49(10):1191-1193.
|
[7] |
Waltimo T, Haapaniemi E, Surakka IL , et al. Post-thrombolytic blood pressure and symptomatic intracerebral hemorrhage[J]. European J Neurology, 2016,23(12):341-348.
|
[8] |
Romano JG, Smith EE, Liang L , et al. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis:a retrospective analysis of the get with the guidelines-stroke registry[J]. JAMA Neurology, 2015,72(4):423.
|
[9] |
常红, 许亚红, 陈琳 . 缺血性脑卒中患者阿替普酶静脉溶栓溶栓后出血的研究进展[J]. 中华护理杂志, 2015,50(4), 341-348.
|
[10] |
Mazya M . Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase:safe implementation of treatments in stroke(SITS)symptomatic intracerebral hemorrhage risk score[J]. Stroke, 2012,43(6):1524.
|
[11] |
Menon BK, Saver JL, Prabhakaran S , et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator[J]. Stroke, 2012,43(9):2293.
|
[12] |
Furie KL, Jayaraman MV . 2018 guidelines for the early management of patients with acute ischemic stroke[J]. Stroke, 2018,118(1):020176.
|
[13] |
Bart M, Demaerschalk DO, Kleindorfer OM, 等. 急性缺血性脑卒中静脉阿替普酶溶栓治疗的纳入和排除标准的科学依据美国心脏协会/美国卒中协会对医疗卫生专业人员发布的声明[J]. 国际脑血管病杂志, 2016,24(4):385-406.
|
[14] |
栾璟煜, 王伊龙 . 阿替普酶急性卒中溶栓安全应用的监测研究(SITS-MOST)[J]. 中国卒中杂志, 2007,2(12):1009-1014.
|
[15] |
Yaghi S, Willey JZ, Cucchiara B , et al. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke:a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2017,48(12):343-361.
|
[16] |
Trouillas P, von Kummer R . Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke[J]. Stroke, 2006,37(2):556-561.
|
[17] |
李雪玲, 王芳 . 浅析牙龈出血的诊断治疗[J]. 中国卫生产业, 2013,10(6):191.
|
[18] |
周理好 . 外科护理学[M]. 南京: 南京大学出版社, 2015: 60.
|
[19] |
Fonarow GC, Zhao X, Smith EE , et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative[J]. JAMA, 2014,311(16):1632-1640.
|
[20] |
Butcher K, Christensen S, Parsons M , et al. Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation[J]. Stroke, 2010,41(1):72-77.
|
[21] |
Ko Y, Park JH, Yang MH , et al. The significance of blood pressure variability for the development of hemorrhagic transformation in acute ischemic stroke[J]. Stroke, 2010,41(11):2512-2518.
|
[22] |
Vemmos KN, Tsivgoulis Q, Spengos K , et al. U-shaped relationship between mortality and admission blood pressure in patients with acute stroke[J]. J Intern Med, 2004,255(2):257-265.
|